Cablivi Interactions
There are 161 drugs known to interact with Cablivi (caplacizumab), along with 2 disease interactions. Of the total drug interactions, 71 are major, 84 are moderate, and 6 are minor.
- View all 161 medications that may interact with Cablivi
- View Cablivi disease interactions (2)
Most frequently checked interactions
View interaction reports for Cablivi (caplacizumab) and the medicines listed below.
- Actimmune (interferon gamma-1b)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Addyi (flibanserin)
- Adzynma (apadamtase alfa, recombinant)
- Aimovig (erenumab)
- Albutein (albumin human)
- Alhemo (concizumab)
- Alphanate (antihemophilic factor/von willebrand factor)
- Altuviiio (antihemophilic factor)
- Alyftrek (deutivacaftor / tezacaftor / vanzacaftor)
- ambrisentan
- amiodarone
- Amondys 45 (casimersen)
- Amvuttra (vutrisiran)
- anagrelide
- Andembry (garadacimab)
- apremilast
- Aristada (aripiprazole)
- Attruby (acoramidis)
- Aubagio (teriflunomide)
- Augtyro (repotrectinib)
- Austedo XR (deutetrabenazine)
- Bafiertam (monomethyl fumarate)
- bedaquiline
- Benlysta (belimumab)
- Brilinta (ticagrelor)
- Rexulti (brexpiprazole)
- Valium (diazepam)
- Xtandi (enzalutamide)
Cablivi disease interactions
There are 2 disease interactions with Cablivi (caplacizumab) which include:
Report options
QR code containing a link to this page
More about Cablivi (caplacizumab)
- Cablivi consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: platelet aggregation inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.